Organogenesis Q1 revenue misses estimates on lower wound care sales

Organogenesis Holdings

07/05/2026 21:40

Overview

Regenerative medicine firm's Q1 revenue missed expectations as it fell 58% yr/yr, driven by lower wound care sales

Adjusted net loss widened sharply from prior year

Company expects 2026 revenue to decline 45%-52% from prior year

Outlook

Organogenesis sees 2026 net revenue between $270 mln and $310 mln

Company expects sequential revenue improvement in Q2, but at a more measured rate

Organogenesis continues to expect strong sequential revenue growth in H2 2026, but low-end guidance assumes prolonged market headwinds

Result Drivers

ADVANCED WOUND CARE DECLINE - Revenue drop driven by a 63% decrease in Advanced Wound Care product sales

INVENTORY WRITE-DOWNS & RESTRUCTURING - Inventory write-downs due to regulatory changes and restructuring charges contributed to losses

Company press release: ID:nGNX2kjT9W

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net product revenue
Miss
$36.3 mln
$43.30 mln (1 Analyst)
Q1 EPS
-$0.44
Q1 Adjusted Net Income
Miss
-$43.7 mln
-$40.50 mln (1 Analyst)
Q1 Net Income
-$53.2 mln
Q1 Adjusted EBITDA
Miss
-$48.2 mln
-$31.40 mln (1 Analyst)
Q1 Operating Income
-$68.9 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Organogenesis Holdings Inc is $8.00, about 212.5% above its May 6 closing price of $2.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)